Crizotinib
An oral tyrosine kinase inhibitor that blocks ALK, ROS1, and MET signaling proteins driving certain lung and other cancers, particularly non-small cell lung cancer with ALK or ROS1 gene rearrangements. It was one of the first targeted therapies to demonstrate dramatic responses based on tumor genetics.
Molekularmasse
450,3000 g/mol
LogP
3,70
TPSA
78,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …
2D-Struktur
Cite this structure
Embed this structure
SMILES
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl
InChI
InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
Molecular Formula
C21H22Cl2FN5O
HBD / HBA
2 / 6
Rotierbare Bindungen
5
Schwere Atome
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An oral tyrosine kinase inhibitor that blocks ALK, ROS1, and MET signaling proteins driving certain lung and other cancers, particularly non-small cell lung cancer with ALK or ROS1 gene rearrangements. It was one of the first targeted therapies to demonstrate dramatic responses based on tumor genetics.
Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.
Yes, Crizotinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL601719. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11626560. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="crizotinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/crizotinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/crizotinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/crizotinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="crizotinib"></drugfyi-drug>